These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9219921

  • 1. 4-Methyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-N-aryl-carboxamides: an approach to combined androgen blockade [5alpha-reductase inhibition with androgen receptor binding in vitro].
    Tolman RL, Sahoo SP, Bakshi RK, Gratale D, Patel G, Patel S, Toney J, Chang B, Harris GS.
    J Steroid Biochem Mol Biol; 1997 Mar; 60(5-6):303-9. PubMed ID: 9219921
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and in vitro activity of 17 beta-(N-alkyl/arylformamido)- and 17 beta-[(N-alkyl/aryl)alkyl/arylamido]-4-methyl-4-aza-3-oxo-5 alpha-androstan-3-ones as inhibitors of human 5 alpha-reductases and antagonists of the androgen receptor.
    Li X, Singh SM, Labrie F.
    J Med Chem; 1995 Mar 31; 38(7):1158-73. PubMed ID: 7707319
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K, Sun J, Wang C, Wang Y, You Q, Xiao H, Xiang H.
    Bioorg Med Chem Lett; 2017 Sep 01; 27(17):4212-4217. PubMed ID: 28757062
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
    di Salle E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, Panzeri A, Délos S, Martin PM.
    J Steroid Biochem Mol Biol; 1998 Feb 01; 64(3-4):179-86. PubMed ID: 9605412
    [Abstract] [Full Text] [Related]

  • 10. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
    Guarna A, Belle C, Machetti F, Occhiato EG, Payne AH, Cassiani C, Comerci A, Danza G, De Bellis A, Dini S, Marrucci A, Serio M.
    J Med Chem; 1997 Mar 28; 40(7):1112-29. PubMed ID: 9089333
    [Abstract] [Full Text] [Related]

  • 11. Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin.
    Mellin TN, Busch RD, Rasmusson GH.
    J Steroid Biochem Mol Biol; 1993 Feb 28; 44(2):121-31. PubMed ID: 8439517
    [Abstract] [Full Text] [Related]

  • 12. 4-Azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor.
    Liang T, Heiss CE, Cheung AH, Reynolds GF, Rasmusson GH.
    J Biol Chem; 1984 Jan 25; 259(2):734-9. PubMed ID: 6693392
    [Abstract] [Full Text] [Related]

  • 13. Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
    Zaccheo T, Giudici D, di Salle E.
    J Steroid Biochem Mol Biol; 1998 Feb 25; 64(3-4):193-8. PubMed ID: 9605414
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
    Stuart JD, Lee FW, Simpson Noel D, Kadwell SH, Overton LK, Hoffman CR, Kost TA, Tippin TK, Yeager RL, Batchelor KW, Bramson HN.
    Biochem Pharmacol; 2001 Oct 01; 62(7):933-42. PubMed ID: 11543729
    [Abstract] [Full Text] [Related]

  • 15. 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase.
    Frye SV, Haffner CD, Maloney PR, Mook RA, Dorsey GF, Hiner RN, Cribbs CM, Wheeler TN, Ray JA, Andrews RC.
    J Med Chem; 1994 Jul 22; 37(15):2352-60. PubMed ID: 8057283
    [Abstract] [Full Text] [Related]

  • 16. Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.
    Frye SV, Haffner CD, Maloney PR, Hiner RN, Dorsey GF, Noe RA, Unwalla RJ, Batchelor KW, Bramson HN, Stuart JD.
    J Med Chem; 1995 Jul 07; 38(14):2621-7. PubMed ID: 7629802
    [Abstract] [Full Text] [Related]

  • 17. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN, Schröder FH.
    BJU Int; 2009 Nov 07; 104(9):1191-7. PubMed ID: 19624596
    [Abstract] [Full Text] [Related]

  • 18. Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding.
    Rasmusson GH, Reynolds GF, Steinberg NG, Walton E, Patel GF, Liang T, Cascieri MA, Cheung AH, Brooks JR, Berman C.
    J Med Chem; 1986 Nov 07; 29(11):2298-315. PubMed ID: 3783591
    [Abstract] [Full Text] [Related]

  • 19. Synthesis of 17beta-N-substituted 19-Nor-10-azasteroids as inhibitors of human 5alpha-reductases I and II.
    Scarpi D, Occhiato EG, Danza G, Serio M, Guarna A.
    Bioorg Med Chem; 2002 Nov 07; 10(11):3455-61. PubMed ID: 12213459
    [Abstract] [Full Text] [Related]

  • 20. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM.
    Cancer Res; 1996 Nov 01; 56(21):4956-64. PubMed ID: 8895750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.